Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec 24;19(1):4.
doi: 10.3390/md19010004.

Fucoidan and Lung Function: Value in Viral Infection

J Helen Fitton  1 , Ah Young Park  1 , Samuel S Karpiniec  1 , Damien N Stringer  1
Affiliations
Review

Fucoidan and Lung Function: Value in Viral Infection

J Helen Fitton et al. Mar Drugs. .

Abstract

Compromised lung function is a feature of both infection driven and non-infective pathologies. Viral infections-including the current pandemic strain SARS-CoV-2-that affect lung function can cause both acute and long-term chronic damage. SARS-CoV-2 infection suppresses innate immunity and promotes an inflammatory response. Targeting these aspects of SARS-CoV-2 is important as the pandemic affects greater proportions of the population. In clinical and animal studies, fucoidans have been shown to increase innate immunity and decrease inflammation. In addition, dietary fucoidan has been shown to attenuate pulmonary damage in a model of acute viral infection. Direct inhibition of SARS-CoV-2 in vitro has been described, but is not universal. This short review summarizes the current research on fucoidan with regard to viral lung infections and lung damage.

Keywords: COPD; corona; fibrosis; fucoidan; influenza; lung; respiratory.

PubMed Disclaimer

Conflict of interest statement

The authors are employees of Marinova Pty Ltd.

References

    1. Weibel E.R. Lung morphometry: The link between structure and function. Cell Tissue Res. 2017;367:413–426. doi: 10.1007/s00441-016-2541-4. - DOI - PubMed
    1. Pereira L., Critchley A.T. The COVID 19 novel coronavirus pandemic 2020: Seaweeds to the rescue? Why does substantial, supporting research about the antiviral properties of seaweed polysaccharides seem to go unrecognized by the pharmaceutical community in these desperate times? J. Appl. Phycol. 2020;32:1875–1877. doi: 10.1007/s10811-020-02143-y. - DOI - PMC - PubMed
    1. Pozharitskaya O.N., Obluchinskaya E.D., Shikov A.N. Mechanisms of Bioactivities of Fucoidan from the Brown Seaweed Fucus vesiculosus L. of the Barents Sea. Mar. Drugs. 2020;18:275. doi: 10.3390/md18050275. - DOI - PMC - PubMed
    1. Pan H., Peto R., Karim Q.A., Alejandria M., Henao-Restrepo A.M., García C.H., Kieny M.-P., Malekzadeh R., Murthy S., Preziosi M.-P., et al. Repurposed antiviral drugs for COVID-19—Interim WHO SOLIDARITY trial results. N. Engl. J. Med. 2020 doi: 10.1056/NEJMoa2023184. - DOI - PMC - PubMed
    1. Blanco-Melo D., Nilsson-Payant B.E., Liu W.C., Uhl S., Hoagland D., Moller R., Jordan T.X., Oishi K., Panis M., Sachs D., et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell. 2020;181:1036–1045.e9. doi: 10.1016/j.cell.2020.04.026. - DOI - PMC - PubMed

LinkOut - more resources